Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease
Open Access
- 15 July 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1620669
Abstract
The mechanistic target of rapamycin (mTOR) signaling pathway is a central regulator of cellular physiology, modulating processes such as metabolism, protein synthesis, growth, and various forms of cell death. Increasing evidence has revealed that dysregulation of mTOR activity, often triggered or exacerbated by aberrant post-translational modifications (PTMs), contributes to the onset and progression of cardiovascular diseases (CVDs), including atherosclerosis, myocardial infarction, heart failure, and ischemia-reperfusion injury. PTMs such as phosphorylation, ubiquitination, SUMOylation, acetylation, and glycosylation alter mTOR's upstream regulators and downstream effectors, influencing the balance between apoptosis, autophagy, pyroptosis, and ferroptosis. These regulatory mechanisms provide a molecular basis for cell fate decisions during cardiovascular stress and injury. In this review, we systematically summarize recent advances in the understanding of PTM-mediated control of mTOR signaling, with a focus on cardiovascular pathophysiology. We also highlight emerging therapeutic strategies that target PTMs or the mTOR axis, including mTOR inhibitors, AMPK activators, proteasome blockers, and SUMOylation modulators, all of which show promise in preclinical or clinical settings. Understanding how PTMs fine-tune mTOR activity and cell death may pave the way for novel, targeted interventions in cardiovascular medicine and offer potential avenues for the development of precision therapies.Keywords
This publication has 308 references indexed in Scilit:
- PINK1 modulates Prdx2 to reduce lipotoxicity‐induced apoptosis and attenuate cardiac dysfunction in heart failure mice with a preserved ejection fractionClinical and Translational Medicine, 2025
- Clinical Decision Support and Cardiometabolic Medication AdherenceJAMA Network Open, 2025
- SENP6‐Mediated deSUMOylation of Nrf2 Exacerbates Neuronal Oxidative Stress Following Cerebral Ischemia and Reperfusion InjuryAdvanced Science, 2024
- Impact of oxytosis on the cross‐talk of mTORC with mitochondrial proteins in drug‐resistant cancer stem cellsJournal of Cellular Physiology, 2024
- Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta‐AnalysisPrenatal Diagnosis, 2024
- Recent advances of PIWI‐interacting RNA in cardiovascular diseasesClinical and Translational Medicine, 2024
- Ubiquitous regulation of cerebrovascular diseases by ubiquitin‐modifying enzymesClinical and Translational Medicine, 2024
- NDP52 SUMOylation contributes to low‐dose X‐rays‐induced cardiac hypertrophy through PINK1/Parkin‐mediated mitophagy via MUL1/SUMO2 signallingJournal of Cellular Physiology, 2023
- Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myelomaInternational Journal of Cancer, 2021
- Fracture Healing in Collagen-Related Preclinical Models of Osteogenesis ImperfectaJournal of Bone and Mineral Research, 2020